Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 83-96

  Sivaraman, Vivek ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

acute myocardial infarction; cardiac pharmacology; heart disease; ischemia reperfusion injury

Indexed keywords

ADENOSINE; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CARDIOVASCULAR AGENT; CYCLOSPORIN A; DELCASERTIB; ERYTHROPOIETIN; GLUCAGON LIKE PEPTIDE 1; GLYCERYL TRINITRATE; HEART RECEPTOR; INHALATION ANESTHETIC AGENT; INSULIN; NICORANDIL; OPIATE; PHOSPHODIESTERASE V INHIBITOR;

HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; INTRACELLULAR SIGNALING; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ACUTE MYOCARDIAL INFARCTION; CARDIAC PHARMACOLOGY; HEART DISEASE; ISCHEMIA-REPERFUSION INJURY;

ANIMALS; CARDIOTONIC AGENTS; DRUG DESIGN; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY;

EID: 84890908941     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413499973     Document Type: Review

References (137)

1. Global Health Observatory, World Health Organization; 2013. http://www.who.int/gho/ncd/mortality-morbidity/en/index.html. Accessed June 18, 2013.
2. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960 ; 70: 68-78
3. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 ; 74 (5). 1124-1136
4. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003 ; 285 (2). H579 - H588
5. Kin H, Zhao ZQ, Sun HY, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004 ; 62 (1). 74-85
6. Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008 ; 79 (3). 377-386
7. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013 ; 123 (1). 92-100
8. Jennings RB, Murry CE, Steenbergen C, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation. 1990 ; 82 (suppl 3). II2 - II12
9. Garcia-Dorado D, Ruiz-Meana M, Inserte J, Rodriguez-Sinovas A, Piper HM. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res. 2012 ; 94 (2). 168-180
10. Eltzschig HK, Eckle T. Ischemia and reperfusion - from mechanism to translation. Nat Med. 2011 ; 17 (11). 1391-1401
11. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 ; 357 (11). 1121-1135
12. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003 ; 83 (4). 1113-1151
13. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?. J Mol Cell Cardiol. 2009 ; 47 (1). 32-40
14. Paiva MA, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther. 2010 ; 24 (1). 25-32
15. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991 ; 84 (1). 350-356
16. Liu GS, Cohen MV, Mochly-Rosen D, Downey JM. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardiol. 1999 ; 31 (10). 1937-1948
17. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007 ; 12 (3-4). 217-234
18. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999 ; 34 (6). 1711-1720
19. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005 ; 45 (11). 1775-1780
20. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006 ; 27 (20). 2400-2405
21. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 ; 115 (12). 1581-1590
22. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006 ; 70 (2). 308-314
23. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J. 2003 ; 146 (1). 146-152
24. Liu Y, Yang X, Yang XM, et al. AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts. Basic Res Cardiol. 2010 ; 105 (1). 129-137
25. Xu Z, Yang XM, Cohen MV, Neumann T, Heusch G, Downey JM. Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol. 2000 ; 32 (12). 2339-2347
26. Xu Z, Downey JM, Cohen MV. Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis. 2003 ; 5 (6). 368-371
27. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 1994 ; 270 (2). 681-689
28. Manolis AJ, Marketou ME, Gavras I, Gavras H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res. 2010 ; 33 (8). 772-777
29. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol. 2000 ; 131 (1). 138-144
30. Jin ZQ, Chen X. Pretreatment with ramiprilat induces cardioprotection against free radical injury in guinea-pig isolated heart: involvement of bradykinin, protein kinase C and prostaglandins. Clin Exp Pharmacol Physiol. 2000 ; 27 (4). 257-262
31. Penna C, Tullio F, Moro F, Folino A, Merlino A, Pagliaro P. Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res Cardiol. 2010 ; 105 (2). 181-192
32. Morris SD, Yellon DM. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol. 1997 ; 29 (7). 1599-1606
33. Jaberansari MT, Baxter GF, Muller CA, et al. Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. J Am Coll Cardiol. 2001 ; 37 (7). 1996-2001
34. Wang X, Wei M, Kuukasjarvi P, et al. The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). Scand Cardiovasc J. 2009 ; 43 (1). 72-79
35. Pedersen CM, Schmidt MR, Barnes G, et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man. Heart. 2011 ; 97 (22). 1857-1861
36. Kirkpatrick JN, St John Sutton M. Assessment of ventricular remodeling in heart failure clinical trials. Curr Heart Fail Rep. 2012 ; 9 (4). 328-336
37. Ungi I, Palinkas A, Nemes A, et al. Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention. Can J Physiol Pharmacol. 2008 ; 86 (12). 827-834
38. Bonnemeier H, Schafer U, Ortak J, et al. Low doses of intracoronary enalaprilat suppress reperfusion-associated ventricular arrhythmias after primary percutaneous coronary interventions for acute myocardial infarction. Pacing Clin Electrophysiol. 2007 ; 30 (suppl 1). S160 - S165
39. Schaefer U, Kurz T, Bonnemeier H, et al. Intracoronary enalaprilat during angioplasty for acute myocardial infarction: alleviation of postischaemic neurohumoral and inflammatory stress?. J Intern Med. 2007 ; 261 (2). 188-200
40. Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol. 1995 ; 268 (5 pt 2). H2157 - H2161
41. Wong GT, Huang Z, Ji S, Irwin MG. Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2010 ; 24 (5). 790-796
42. Wong GT, Li R, Jiang LL, Irwin MG. Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand. 2010 ; 54 (4). 510-518
43. Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol. 2003 ; 35 (7). 709-718
44. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005 ; 54 (1). 146-151
45. Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther. 2012 ; 136 (3). 267-282
46. Simsek S, de Galan BE. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes. Curr Opin Lipidol. 2012 ; 23 (6). 540-547
47. Chinda K, Chattipakorn S, Chattipakorn N. Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res. 2012 ; 9 (4). 256-269
48. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010 ; 298 (5). H1454 - H1465
49. Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010 ; 59 (4). 1063-1073
50. Hausenloy DJ, Yellon DM. Taking lizard saliva to heart. Eur Heart J. 2012 ; 33 (12). 1426-1430
51. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012 ; 33 (12). 1491-1499
52. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Cir Cardiovasc Interv. 2012 ; 5 (2). 288-295
53. Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res. 2005 ; 68 (1). 8-17
54. Hayek S, Nemer M. Cardiac natriuretic peptides: from basic discovery to clinical practice. Cardiovasc Ther. 2011 ; 29 (6). 362-376
55. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol. 2006 ; 101 (4). 311-318
56. Hong L, Xi J, Zhang Y, et al. Atrial natriuretic peptide prevents the mitochondrial permeability transition pore opening by inactivating glycogen synthase kinase 3beta via PKG and PI3K in cardiac H9c2 cells. Eur J Pharmacol. 2012 ; 695 (1-3). 13-19
57. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): 2 randomised trials. Lancet. 2007 ; 370 (9597). 1483-1493
58. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J. 2008 ; 29 (12). 1485-1494
59. Kuga H, Ogawa K, Oida A, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J. 2003 ; 67 (5). 443-448
60. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002 ; 106 (23). 2973-2979
61. Ong SG, Hausenloy DJ. Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacol Ther. 2012 ; 136 (1). 69-81
62. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res. 2005 ; 2 (5). 387-399
63. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005 ; 293 (1). 90-95
64. Nishihara M, Miura T, Miki T, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol. 2007 ; 43 (5). 564-570
65. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart. 2011 ; 97 (19). 1560-1565
66. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011 ; 305 (18). 1863-1872
67. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv. 2010 ; 3 (5). 408-413
68. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J. 2010 ; 31 (21). 2593-2600
69. Mocini D, Muso P, Guendouz E, et al. Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery. Perfusion. 2008 ; 23 (3). 187-192
70. Joyeux-Faure M, Durand M, Bedague D, et al. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study. Fundam Clin Pharmacol. 2012 ; 26 (6). 761-770
71. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol. 2011 ; 147 (1). 124-131
72. Prunier F, Biere L, Gilard M, et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012 ; 163 (2). 200-207
73. Taniguchi N, Nakamura T, Sawada T, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J. 2010 ; 74 (11). 2365-2371
74. Ozawa T, Toba K, Suzuki H, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J. 2010 ; 74 (7). 1415-1423
75. Andreotti F, Agati L, Conti E, et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of exogenous erythropoietin in acute myocardial infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis. 2009 ; 28 (4). 489-495
76. Minamino T, Toba K, Higo S, et al. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial. Cardiovasc Drugs Ther. 2012 ; 26 (5). 409-416
77. Suh JW, Yoon YE, Oh IY, et al. A single-center prospective randomized controlled trial evaluating the safety and efficacy of intracoronary erythropoietin delivery before reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'. Contemp Clin Trials. 2013 ; 35 (1). 145-150
78. Lou M, Garrett TP, McKern NM, et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci USA. 2006 ; 103 (33). 12429-12434
79. Baines CP, Wang L, Cohen MV, Downey JM. Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol. 1999 ; 94 (3). 188-198
80. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001 ; 89 (12). 1191-1198
81. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol. 2006 ; 38 (3). 414-419
82. Zhang HF, Fan Q, Qian XX, et al. Role of insulin in the anti-apoptotic effect of glucose-insulin-potassium in rabbits with acute myocardial ischemia and reperfusion. Apoptosis. 2004 ; 9 (6). 777-783
83. Zhang HX, Zang YM, Huo JH, et al. Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs. J Cardiovasc Pharmacol. 2006 ; 48 (6). 306-313
84. Zhu P, Lu L, Xu Y, Greyson C, Schwartz GG. Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2000 ; 278 (2). H595 - H603
85. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005 ; 293 (4). 437-446
86. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA. 2007 ; 298 (20). 2399-2405
87. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012 ; 307 (18). 1925-1933
88. Fan Y, Zhang AM, Xiao YB, Weng YG, Hetzer R. Glucose-insulin-potassium therapy in adult patients undergoing cardiac surgery: a meta-analysis. Eur J Cardiothorac Surg. 2011 ; 40 (1). 192-199
89. Davis RF, DeBoer LW, Rude RE, Lowenstein E, Maroko PR. The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion. Anesthesiology. 1983 ; 59 (5). 402-411
90. Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology. 1997 ; 86 (3). 699-709
91. Preckel B, Schlack W, Comfere T, Obal D, Barthel H, Thamer V. Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth. 1998 ; 81 (6). 905-912
92. Frassdorf J, De Hert S, Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth. 2009 ; 103 (1). 89-98
93. Penta de Peppo A, Polisca P, Tomai F, et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. Ann Thorac Surg. 1999 ; 68 (1). 112-118
94. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation. 1999 ; 100 (19 suppl). II340 - II344
95. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology. 2004 ; 101 (1). 9-20
96. de Hert SG, Van der Linden PJ. Left ventricular function after cardiopulmonary bypass is related to the length-dependent regulation of myocardial function. Anesth Analg. 2004 ; 99 (1). 311-312
97. Garcia C, Julier K, Bestmann L, et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth. 2005 ; 94 (2). 159-165
98. De Hert S, Vlasselaers D, Barbe R, et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia. 2009 ; 64 (9). 953-960
99. Kukreja RC, Salloum FN, Das A, Koka S, Ockaili RA, Xi L. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol. 2011 ; 16 (4). e30 - e35
100. Reffelmann T, Kloner RA. Phosphodiesterase 5 inhibitors: are they cardioprotective?. Cardiovasc Res. 2009 ; 83 (2). 204-212
101. Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs. 2008 ; 68 (3). 383-397
102. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012 ; 59 (1). 9-15
103. Sogo N, Campanella C, Webb DJ, Megson IL. S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol. 2000 ; 131 (6). 1236-1244
104. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987 ; 2 (8567). 1057-1058
105. Lefer AM. Nitric oxide: nature's naturally occurring leukocyte inhibitor. Circulation. 1997 ; 95 (3). 553-554
106. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998 ; 97 (9). 916-931
107. Kanno S, Lee PC, Zhang Y, et al. Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation. 2000 ; 101 (23). 2742-2748
108. Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005 ; 115 (5). 1232-1240
109. Cohen MV, Yang XM, Downey JM. Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res. 2006 ; 70 (2). 231-239
110. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008 ; 118 (19). 1915-1919
111. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988 ; 1 (8594). 1088-1092
112. Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand. 2012 ; 56 (1). 30-38
113. Kleinbongard P, Thielmann M, Jakob H, Peters J, Heusch G, Kottenberg E. Nitroglycerin does not interfere with protection by remote ischemic preconditioning in patients with surgical coronary revascularization under isoflurane anesthesia. Cardiovasc Drugs Ther. 2013 ; 27 (4). 359-361
114. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003 ; 41 (3). 508-515
115. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol. 2003 ; 41 (4). 649-656
116. Vilahur G, Casani L, Pena E, Duran X, Juan-Babot O, Badimon L. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis. 2009 ; 206 (1). 95-101
117. Nusca A, Melfi R, Patti G, Di Sciascio G. Statin loading for acute coronary syndromes. Curr Opin Cardiol. 2010 ; 25 (4). 373-378
118. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010 ; 3 (3). 332-339
119. Ludman AJ, Hausenloy DJ, Babu G, et al. Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Res Cardiol. 2011 ; 106 (6). 1387-1395
120. Churchill EN, Mochly-Rosen D. The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem Soc Trans. 2007 ; 35 (pt 5). 1040-1042
121. Sivaraman V, Hausenloy DJ, Kolvekar S, et al. The divergent roles of protein kinase C epsilon and delta in simulated ischaemia-reperfusion injury in human myocardium. J Mol Cell Cardiol. 2009 ; 46 (5). 758-764
122. Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008 ; 117 (7). 886-896
123. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target?. Nat Rev Drug Discov. 2012 ; 11 (12). 937-957
124. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs. 2011 ; 71 (9). 1105-1119
125. Pain T, Yang XM, Critz SD, et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. Circ Res. 2000 ; 87 (6). 460-466
126. Sanada S, Kitakaze M, Asanuma H, et al. Role of mitochondrial and sarcolemmal K(ATP) channels in ischemic preconditioning of the canine heart. Am J Physiol Heart Circ Physiol. 2001 ; 280 (1). H256 - H263
127. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005 ; 112 (9). 1284-1288
128. Yamamoto S, Yamada T, Kotake Y, Takeda J. Cardioprotective effects of nicorandil in patients undergoing on-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2008 ; 22 (4). 548-553
129. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999 ; 341 (pt 2). 233-249
130. Hausenloy DJ, Lim SY, Ong SG, Davidson SM, Yellon DM. Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning. Cardiovasc Res. 2010 ; 88 (1). 67-74
131. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovasc Res. 2002 ; 55 (3). 534-543
132. Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM. Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol. 2005 ; 289 (1). H237 - H242
133. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008 ; 359 (5). 473-481
134. Mewton N, Croisille P, Gahide G, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010 ; 55 (12). 1200-1205
135. Yang XM, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013 ; 27 (2). 109-115
136. Yang XM, Liu Y, Cui L, et al. Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013 ; 1 (8(3). 251-26
137. Barrabes JA, Inserte J, Mirabet M, et al. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost. 2010 ; 104 (1). 128-135